CoVIg-19 Plasma Alliance
Saturday, April 3, 2021 2:00PM IST (8:30AM GMT)
Osaka, Japan & King of Prussia, Pa., United States:
Phase 3 Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) Clinical Trial Sponsored and Funded by the National Institute of Allergy and Infectious Diseases (NIAID), Part of the National Institutes of Health (NIH), Did Not Meet Its Endpoints to Show Efficacy in Adults Hospitalized With COVID-19
The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised in the trial.
5 Most Valuable Australian Companies
In this article, we are going to list the
5 Most Valuable Australian Companies. To read our detailed analysis of the Australian economy, please go to the
Market cap: $86.8 billion
Melbourne-based biotech giant CSL Limited ranks 5th on our list of the 15 most valuable Australian companies. The company develops plasma therapies through its CSL Behring segment and produces influenza vaccines through its CSL Seqirus segment. In February 2021, CSL announced its partnership with AstraZeneca (LON: AZN) to produce 30 million doses of the Oxford University vaccine. CSL has also joined the COVIg-19 Plasma Alliance, which develops anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine to treat hospitalized adults at risk of severe complications of COVID-19. Microsoft (NASDAQ: MSFT) provides technical support in the COVIg-19 Plasma Alliance website and Plasma Bot for donor recruitment.